Jason C Park

US Patent:

8333803, Dec 18, 2012

Filed:

Nov 19, 2009

Appl. No.:

12/621890

Inventors:

Jason Park - Brooklyn NY, US
Aaron Barere - Hoboken NJ, US
Christopher T. Wagner - Flemington NJ, US
Robert Kiefer - Quakertown PA, US
E. Skott Greenhalgh - Lower Gwynedd PA, US

Assignee:

Lifecell Corporation - Branchburg NJ

International Classification:

A61F 2/08

US Classification:

623 1314

Abstract:

The present disclosure provides an implantable medical device comprising a composite graft material including a first biologic component, such as an acellular tissue matrix, and a second non-biologic component.

US Patent:

20050218046, Oct 6, 2005

Filed:

Feb 5, 2004

Appl. No.:

10/771342

Inventors:

Daryl Mileaf - Hanover MD, US
Stephanie Lauretano - Ellicott City MD, US
Jason Park - Baltimore MD, US
Patrick Cowgill - Cantonsville MD, US
Stanley Wakamiya - Ellicott City MD, US
Charles Shaw - Fairfax VA, US

Assignee:

Northrop Grumman Corporation - Los Angeles CA

International Classification:

B07C005/00
G06K009/00

US Classification:

209584000

Abstract:

A two-pass mail sorting method for sorting mail into delivery point order. In one embodiment, the method includes the step of forming a delivery point group comprising delivery points that are temporarily or permanently on hold. In another embodiment, the method includes the step of processing saturation mail only after performing the first-pass mail sort. In another embodiment, the method includes partitioning a mail sorting system comprising N outputs into X virtual mail sorting systems having N/X outputs.

US Patent:

20080041770, Feb 21, 2008

Filed:

Feb 23, 2007

Appl. No.:

11/709880

Inventors:

Daryl Mileaf - Hanover MD, US
Patrick Cowgill - Crestwood KY, US
Jason Park - Abingdon MD, US
Jeff Lindhurst - Crofton MD, US
Sean Ledford - Perry Hall MD, US
Stephanie Miskiewicz - Columbia MD, US
Stanley Wakamiya - Ellicott City MD, US
Charles Shaw - Fairfax VA, US
Bruno Cartal - Rockville MD, US
Emmanuel Delbe - Bethesda MD, US
Jacques Petit - Bethesda MD, US
Pierre Campagnolle - Hanover MD, US
Nicholas Basset - Rockville MD, US
Laurent Buffat - Columbia MD, US

Assignee:

Northrop Grumman Systems Corporation - Los Angeles CA

International Classification:

B07C 3/20

US Classification:

209584000

Abstract:

Embodiments of the present invention provide a method of using a multi-input sorting machine for sorting mail in delivery point order.

US Patent:

20130053960, Feb 28, 2013

Filed:

Sep 14, 2012

Appl. No.:

13/616556

Inventors:

Jason Park - Brooklyn NY, US
Aaron Barere - Hoboken NJ, US
Christopher T. Wagner - Flemington NJ, US
Robert Kiefer - Quakertown PA, US
E. Skott Greenhalgh - Lower Gwynedd PA, US

International Classification:

A61F 2/08
B23P 11/00

US Classification:

623 1317, 29428

Abstract:

The present disclosure provides an implantable medical device comprising a composite graft material including a first biologic component, such as an acellular tissue matrix, and a second non-biologic component.

US Patent:

20220387470, Dec 8, 2022

Filed:

May 13, 2022

Appl. No.:

17/743679

Inventors:

- Cambridge MA, US
Alexandra Masu Cantley - New York NY, US
Jason Park - West Newton MA, US
Douglas Gowers Cole - Wayland MA, US

International Classification:

A61K 31/7084
A61P 35/00
A61K 45/06

Abstract:

In one aspect, the invention provides methods of increasing immune response by administering postcellular signaling factors produced by cells exposed to a stress condition. In one aspect, the invention provides methods of increasing immune response by administering in combination (a) a Stimulator of Interferon Genes (STING) agonist and (b) a purinergic receptor agonist. The increase in immune response may be used, for example, for treatment of infection or cancer. The invention also provides screening assays for identification of compounds that induce production of postcellular signaling factors which are also immunostimulatory agents. The invention further provides methods for identifying postcellular signaling factors with immunostimulatory activity. In another aspect, the invention provides methods of decreasing immune response by administering to a cell, tissue or subject a purinergic receptor antagonist alone or in combination with a Stimulator of Interferon Genes (STING) antagonist.

US Patent:

20230114107, Apr 13, 2023

Filed:

Dec 17, 2020

Appl. No.:

17/787287

Inventors:

- Cambridge MA, US
Alexandra Masu Cantley - New York NY, US
Jason Park - West Newton MA, US
Darby Rye Schmidt - Arlington MA, US
Peter Joseph Gough - Wayne PA, US

International Classification:

A61K 31/472
A61K 31/69
A61K 31/635
A61K 35/768
A61K 35/761
A61K 31/444
A61K 31/436
A61K 31/496
A61K 31/506
A61K 31/5025
A61K 31/517
A61K 31/5377
A61K 31/437
A61K 31/4545
A61K 31/519
A61K 31/502
A61K 39/395
A61K 31/4365
A61K 31/4375
A61P 35/00

Abstract:

The invention provides methods of treating a cancer in a subject, comprising administering to the subject a combination of (a) an anti-neoplastic agent and (b) an agent that induces iron-dependent cellular disassembly, thereby treating the cancer in the subject. In some embodiments, the cancer is resistant to the anti-neoplastic agent.

US Patent:

20210299155, Sep 30, 2021

Filed:

May 6, 2021

Appl. No.:

17/313296

Inventors:

- Cambridge MA, US
Alexandra Masu Cantley - New York NY, US
Jason Park - West Newton MA, US
Douglas Gowers Cole - Wayland MA, US

International Classification:

A61K 31/7084
A61K 45/06
A61P 35/00

Abstract:

In one aspect, the invention provides methods of increasing immune response by administering posteellular signaling factors produced by cells exposed to a stress condition. In one aspect, the invention provides methods of increasing immune response by administering in combination (a) a Stimulator of Interferon Genes (STING) agonist and (b) a purinergic receptor agonist. The increase in immune response may be used, for example, for treatment of infection or cancer. The invention also provides screening assays for identification of compounds that induce production of postcellular signaling factors which are also immunostimulatory agents. The invention further provides methods for identifying postcellular signaling factors with immunostimulatory activity. In another aspect, the invention provides methods of decreasing immune response by administering to a cell, tissue or subject a purinergic receptor antagonist alone or in combination with a Stimulator of Interferon Genes (STING) antagonist.

US Patent:

20210283091, Sep 16, 2021

Filed:

Jun 14, 2019

Appl. No.:

17/252214

Inventors:

- Cambridge MA, US
Alexandra Masu Cantley - New York NY, US
Jason Park - West Newton MA, US

International Classification:

A61K 31/245
A61K 33/04
A61K 31/45
A61K 31/095
A61K 31/137
A61K 31/277
A61K 31/353
A61K 31/407
A61K 31/122
A61K 31/381
A61K 31/355
A61K 31/202
A61K 31/05
A61K 31/085
A61K 31/499
A61K 38/12
A61K 31/16
A61K 31/4418
A61K 31/4412
A61K 49/00
A61K 31/517
A61K 31/437
A61K 31/03
A61K 31/185
A61K 31/357
A61K 31/40
A61K 31/405
A61K 31/366
A61K 31/47
A61K 31/22
A61K 31/505
A61K 31/44
A61K 31/655
A61K 33/243
A61K 38/51
A61K 33/00
A61K 33/20
A61K 33/26
A61K 31/455
A61K 31/198
A61P 37/06
A61P 35/00
G01N 33/50

Abstract:

The invention provides methods of decreasing immune response by inhibiting iron-dependent cellular disassembly. The decrease in immune response may be used, for example, for treatment of a disorder associated with iron-dependent cellular disassembly, including an autoimmune disorder, allergy, or an inflammatory disorder. The invention also provides screening assays for identification of compounds that inhibit iron-dependent cellular disassembly and are also immunoinhibitory agents.